SCNI Scinai Immunotherapeutics Ltd.

BEARISH Impact: 6/10 EFFECT
Horizon days Filed May 20, 2026 Processed 24d 1h ago SEC 9999999995-26-001706
IPO/offering going effective
Latest settled — T+5d
SCNI ▼ -6.07% at T+5d
SHORT call ✓ call won +6.07% · α vs SPY +7.87% · entry $0.4780 → $0.4490
Next anchor: T+20d in 5d
Currently $0.3310 · +30.75% from $0.4780 entry (call sign-flipped)
Entry anchored
May 20, 2026
via day open
T+1d
+3.97%
call -3.97% · α -3.78%
$0.4970
settled 23d ago
T+5d
-6.07%
call +6.07% · α +7.87%
$0.4490
settled 16d ago
T+20d
call — · α —
in 5d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Scinai Immunotherapeutics' shelf registration on Form F-3 (File No. 333-295698) was declared effective by the SEC on May 19, 2026. This allows the company to offer and sell securities (equity, debt, or other instruments) from time to time at its discretion. For a micro-cap biotech with a $2M market cap, this creates a tangible dilution overhang and signals potential near-term capital-raising activity.

Actionable Insight

Short-term bearish pressure expected on dilution fears typical of a post-effective micro-cap shelf. Traders should monitor for an 8-K or prospectus supplement (pricing announcement) — especially since the cross-filing actuarial data marks this effect-ipo-context + effect-shelf-context combo as an amplifier, suggesting heightened propensity to tap the shelf quickly. If the company draws the shelf at a large discount to market, expect 20-40% downside. Conversely, if no offering occurs within 30 days, bearish overhang may partially fade.

Key Facts

  • Effectiveness date: May 19, 2026
  • Form F-3 shelf registration (File No. 333-295698) covering unspecified securities
  • Company market cap is approximately $2M; minimal absolute dollar offering could cause significant dilution
  • Company has no disclosed revenue or pipeline revenue milestones in this filing
  • Historical calibration data shows a net average alpha of -2.39% at T+20 for similar filing-report segment

Financial Impact

Potential dilutive offering; exact size undisclosed but at $2M market cap, even a small $500K-$1M raise could dilute existing shareholders by 20-50%

dilutionequity

Risk Factors

  • Immediate dilution risk if shelf is drawn down quickly
  • Micro-cap biotech with no disclosed revenue may face severe adverse selection in equity markets
  • Cross-filing amplifier verdict suggests historically elevated odds of near-term capital raise after shelf effectiveness

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (7 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001706
Document: 9999999995-26-001706-index.html9999999995-26-001706
Document: 9999999995-26-001706.txt9999999995-26-001706
5 reports for SCNI
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+20▲ +27.46%May 8, 2026
Filters
Rows
Reports for SCNI — sortable, filterable
Type Now
Jun 8, 2026
4d ago
6-K
NEUTRAL ★ 2/10
$0.4111 awaiting T+5awaiting T+5$0.3310 (−19.48%)
May 20, 2026
24d ago
EFFECT
BEARISH ★ 6/10
$0.4780 $0.4490▲ +6.07%▲ +7.87%$0.3310 (+30.75%)
May 8, 2026
5w ago
6-K
BEARISH ★ 7/10
$0.5680 $0.5350▲ +5.81%▲ +7.27%$0.3310 (+41.73%)
Apr 27, 2026
6w ago
6-K
BEARISH ★ 7/10
$0.5840 $0.6450▼ −10.45%▼ −8.75%$0.3310 (+43.32%)
Apr 1, 2026
10w ago
20-F
BEARISH ★ 7/10
$0.6390 $0.5900▲ +7.67%▲ +11.43%$0.3310 (+48.20%)
Showing 5 of 5

US Market Status

Market Closed — Opens Mon (49h 31m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access